Two National Guard members shot near White House
Edwards Lifesciences Corp (EW) stock has reached a new 52-week high, peaking at 87.25 USD. This milestone marks a significant point for the company, reflecting a robust performance over the past year. The stock’s value has seen a notable increase, with a 1-year total return of 21.34% and impressive YTD gains of 17.28%, indicating strong investor confidence and positive market sentiment. InvestingPro data shows the company maintains a GOOD financial health score of 2.96, with management aggressively buying back shares. This upward trend suggests that the company has been successful in its operational strategies, potentially driven by advancements in its medical technologies and a solid financial performance. With revenue growth of 10.6% and a P/E ratio of 37.96, the stock trades at premium valuations. As Edwards Lifesciences continues to innovate in the healthcare sector, investors will be keenly watching to see if this momentum can be sustained in the coming months. Analysts remain optimistic, with a consensus Buy recommendation and a high price target of $105.Discover more insights with InvestingPro, which offers 11 additional ProTips and comprehensive analysis on Edwards Lifesciences, one of 1,400+ US equities with detailed Pro Research Reports.
In other recent news, Edwards Lifesciences reported robust financial performance for the third quarter of 2025, with adjusted earnings per share reaching $0.67, surpassing Wall Street’s forecast of $0.59. The company’s revenue also exceeded expectations, totaling $1.55 billion compared to the anticipated $1.5 billion. This strong quarterly performance led Bernstein to raise its price target for Edwards Lifesciences to $90, citing notable growth in the transcatheter aortic valve replacement (TAVR) segment. Canaccord Genuity also adjusted its price target from $81 to $84, maintaining a Hold rating based on the company’s solid third-quarter results. Additionally, Raymond James upgraded the company’s stock rating to Outperform, setting a price target of $96, indicating increased confidence in the company’s prospects. Piper Sandler reiterated an Overweight rating with a $95 price target, anticipating further guidance at the upcoming investor day. These developments highlight the positive sentiment among analysts regarding Edwards Lifesciences’ recent performance and future outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.